CSIMarket Company Name, Ticker, Competitors, else..
 
Cvrx inc   (NASDAQ: CVRX)
 
Price: $2.9600 $0.01 0.339%
Day's High: $2.990000009536743 Week Perf: -12.17 %
Day's Low: $ 2.81 30 Day Perf: -42.8 %
Volume (M): 737,607 52 Wk High: $ 11.30
Volume (M$): $ 0 52 Wk Avg: $7.07
Open: $2.97 52 Wk Low: $2.20



 Market Capitalization (Millions $) 78
 Shares Outstanding (Millions) 26
 Employees 223
 Revenues (TTM) (Millions $) 58
 Net Income (TTM) (Millions $) -53
 Cash Flow (TTM) (Millions $) -30
 Capital Exp. (TTM) (Millions $) 1

Business Description


CvRx Inc. is a medical device company based in Minneapolis, Minnesota. It specializes in developing implantable technologies for the treatment of cardiovascular diseases. The company's main product is the BAROSTIM NEO System, which is an implantable device that delivers electrical signals to the baroreceptors in the carotid sinus. This therapy helps to regulate blood pressure and improve cardiac function in patients suffering from hypertension or heart failure. CvRx Inc. has gained recognition for its innovative approach to cardiovascular care and is dedicated to improving patient outcomes and quality of life.


   Company Address: 9201 West Broadway Avenue Minneapolis 55445 MN
   Company Phone Number: 416-2840   Stock Exchange / Ticker: NASDAQ CVRX


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
BAX   -1.85%    
BDX   -1.38%    
BSX   -1.45%    
EW        0.28% 
SYK   -1.22%    
TFX        2.7% 
• View Complete Report
   



Product Service News

CVRx Highlights Barostims Quality of Life Benefits Amidst Year-to-Date Stock Struggles,

Published Thu, Sep 12 2024 12:00 PM UTC

CVRx Publishes New Data Showcasing Long-Term Quality of Life Benefits of Barostim in Heart Failure Patients CVRx Inc. (NASDAQ: CVRX) has announced the publication of new data highlighting the long-term benefits of its innovative Barostim therapy, which offers promising quality of life enhancements for patients suffering from heart failure with reduced ejection fraction. The ...
Product Service News

CVRx Secures Increased Inpatient Payment for Barostim Procedure A Game Changer in Heart Failure Treatment

Published Fri, Aug 2 2024 12:00 PM UTC

In a significant development for the cardiovascular medical device landscape, CVRx, Inc. (NASDAQ: CVRX) announced on August 2, 2024, that the Centers for Medicare and Medicaid Services (CMS) has redefined payment parameters for the Barostim implant procedure, marking a crucial milestone for hospital reimbursement under the Fiscal Year (FY) 2025 Medicare Hospital Inpatient Pr...
Clinical Study

Barostim Therapy: A Promising Approach for Heart Failure Management

Published Mon, Apr 15 2024 11:30 AM UTC

Heart failure affects millions of individuals worldwide and is associated with significant morbidity and mortality rates. Despite advances in medical management, many patients experience persistent symptoms and reduced quality of life. However, recent data from the BeAT-HF trial and abstracts presented at the THT conference suggest that Barostim Therapy holds promise as an i...
Product Service News

CVRx Secures FDA Approval for Expanded Labeling of Barostim, Bolstering U.S. Market Opportunity

Published Tue, Dec 26 2023 1:05 PM UTC

CVRx, a leading medical technology company, has recently attained FDA approval for expanded labeling of its innovative Barostim therapy. This development marks a significant milestone in the field of cardiac healthcare, as it not only amplifies the U.S. annual market prognosis but also underscores the efficacy of CVRx s long-term BeAT-HF data. With this regulatory nod, CVRx ...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 1.35
Price to Sales (Expected) -
Price to Book 2.68
PEG (TTM) -

Financial Strength Current
Quick Ratio 7.62
Working Capital Ratio 10.2
Leverage Ratio (MRQ) 2.43
Total Debt to Equity 2.01
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -2.02 $
Revenues (TTM) 2.2 $
Cash Flow (TTM) -
Cash 2.74 $
Book Value 1.1 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 259,682
Net Income per Employee (TTM) -236,143
Receivable Turnover Ratio (TTM) 6.59
Inventory Turnover Ratio (TTM) 0.59
Asset Turnover Ratio (TTM) 0.53

Profitability Ratios Current
Gross Margin (MRQ) 92.8 %
Operating Margin (MRQ) -87.61 %
Net Margin (MRQ) -94.52 %
Net Cash Flow Margin (MRQ) -24.53 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -



Cvrx Inc's Segments
U S    98.34 % of total Revenue
Other countries    8.06 % of total Revenue





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.